Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Vote in favor of your Number one Kind of Shades - 2Israel says Iran's military industry will be destroyed 'within days'
- 3Jill Hennessy was a '90s TV staple. Now she's in her fearless era.
- 4It May Take a Year to Restore Abu Dhabi Aluminum Output, EGA Says
- 521 Incredibly Entertaining Contemplations To Observe Consistently
- Who is Artemis? Meet the Greek goddess who inspired NASA's return to the moon
- The Main 15 Powerful Business Heads of Today
- ADHD drugs work, but not the way experts thought
- Alice Wong, founder of the Disability Visibility Project, dies at 51
- An Extended time of Careful Nurturing: Individual Bits of knowledge on Bringing up Youngsters
- Vote in favor of your #1 Kind of Cap
- Find the Wonders of the Silk Street: Following the Antiquated Shipping lanes
- This St Nick Truly Can Advise How To Drink And Hack Your Headache
- Interstellar comet 3I/ATLAS isn't an alien spacecraft, astronomers confirm. 'In the end, there were no surprises.'
